RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - Aspetti molecolari di patologie conformazionali proteiche. Ruolo dei fattori ambientali sulle variazioni strutturali di proteine per la progettazione e la sintesi di agenti ad attività antiaggregante, antiossidante, antiglicante e chelante nonchè per applicazioni in diagnostica.
• 2 - Interattomi proteici: identificazione e caratterizzazione di network cellulari in differenti condizioni fisiopatologiche
• 3 - Supramolecular complexes of sorcin in the generation and regulation of Calcium-dependent cellular functions
• 4 - Proprieta’ strutturali e attivita’ funzionale di un complesso proteico modificante la cromatina nell’uomo
• 5 - Basi molecolari della citotossicità indotta dai diversi stati di aggregazione di beta amiloide: studio multidisciplinare in vitro, su colture cellulari e su modello animale.
• 6 - RUOLO DELLE INTERAZIONI MOLECOLARI NELL'ACQUISIZIONE DELLA STRUTTURA FUNZIONALE DI PROTEINE MODELLO
• 7 - Caratterizzazione molecolare dell'eritropoiesi:analisi post-genomica e funzionale del profilo di espressione proteica
• 8 - Genomica strutturale di metalloproteine e delle loro interazioni funzionali
• 9 - INTERRELAZIONI TRA LA PERMEABILITÀ IONICA DI MEMBRANA E LO STATO REDOX INTRACELLULARE NEI PROCESSI NEURODEGENERATIVI: AZIONE DEI PEPTIDI AMILOIDI IN CELLULE NEURONALI E GLIALI.
• 10 - Processi chimici e modificazioni strutturali nella neurodegenerazione

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze chimiche
  • CHIMICA GENERALE E INORGANICA
  • CHIMICA FARMACEUTICA
• Area scientifico disciplinare: Scienze biologiche
  • BIOCHIMICA

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF (biocides, pest repellants or attractants, or plant growth regulators, containing micro-organisms, viruses, microbial fungi, enzymes, fermentates or substances produced by or extracted from micro-organisms or animal material A01N63/00; food compositions A21, A23; medicinal preparations A61K; chemical aspects of, or use of materials for, bandages, dressings, absorbent pads or surgical articles A61L; fertilisers C05); PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS (preservation of living parts of humans or animals A01N1/02); MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (micro-biological testing media C12Q)
  • ORGANIC CHEMISTRY (such compounds as the oxides, sulfides, or oxysulfides of carbon, cyanogen, phosgene, hydrocyanic acid or salts thereof C01; products obtained from layered base-exchange silicates by ion-exchange with organic compounds such as ammonium, phosphonium or sulfonium compounds or by intercalation of organic compounds C01B33/44; macromolecular compounds C08; dyes C09; fermentation products C12; fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture C12P; production of organic compounds by electrolysis or electrophoresis C25B3/00, C25B7/00)
    • PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

Classificazione geografica

• Regione: Sicilia

Bibliografia

[1] R. W. Carrell, D. A. Lomas, Conformational disease, Lancet, 1997, 350: 134–38.
[2] C. A Ross and M. A Poirier, Protein aggregation and neurodegenerative disease, Nature Medicine, 2004, S10.
[3] C. Soto, Unfolding the role of protein misfolding in neurodegenerative disases, Nature Reviews, 2003, 4, 49-60.
[4] Hashimoto M., Hsu L. J., Xia Y., Takeda A. M., Sundsmo M. and Masliah E. (1999) Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuroreport 10: 717–721.
[5] Paik S. R., Shin H. J., Lee J. H., Chang C. S. and Kim J. (1999) Copper(II)-induced self-oligomerization of alpha-synuclein. Biochem. J. 340: 821–828.
[6] Bush A. I., Moir R. D., Rosenkranz K. M. and Tanzi R. E. (1995) Zinc and Alzheimer’s disease. Science 268: 1921–1922.
[7] Morgan C. J., Gelfand M., Atreya C. and Miranker A. D. (2001) Kidney dialysis-associated amyloidosis: a molecular role for copper in fiber formation. J. Mol. Biol. 309: 339–345.
[8] Ashley I. Bush, The metallobiology of Alzheimer’s disease TRENDS in Neurosciences Vol.26 No.4 April 2003 207-214.
[9] C. J. Frederickson, Jae-Young Koh and A.I. Bush, The neurobiology of Zinc in health and diseases, Nature Reviews, Vol. 6, 2005; 449-462.
[10] J. K. Andersen, Oxidative stress in neurodegeneration: cause or consequence? Nature Reviews, 2004, S18-25.
[11] A. I. Bush, Metal complexing agents as therapies for Alzheimer’s disease, Neurobiology of Aging, 23 (2002) 1031–1038.
[12] A. J. McClellan, S. Tam, D. Kaganovich and J. Frydman, Protein quality control: chaperones culling corrupt conformations, Nature Cell Biology, 7, 2005, 736-745.
[13] Wolf, D. H. & Hilt, W. The proteasome: a proteolytic nanomachine of cell regulation and waste disposal. Biochim. Biophys. Acta 1695, 19–31 (2004).
[14] A. Hershko, & Ciechanover, A. The ubiquitin system. Annu. Rev. Biochem. 67, 425–479 (1998).
[15] Hoppe, T. Multiubiquitylation by E4 enzymes: ‘one size’ doesn’t fit all. Trends Biochem. Sci. 30, 183–187 (2005).
[16] C. A. Ross and C. M. Pickart, The ubiquitin–proteasome pathway in Parkinson’s disease and other neurodegenerative diseases, TRENDS in Cell Biology Vol.14, 2004.
[17] 5 Yang, Y. and Yu, X. (2003) Regulation of apoptosis: the ubiquitous way. FASEB J. 17, 790–799.
[18] Adams, J. (2002) Proteasome inhibitors as new anticancer drugs. Curr. Opin. Oncol. 14, 628–634.
[19] Vassilev, L.T. et al. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844–848.
[20] C. M. Pickart and D. Fushman, Polyubiquitin chains: polymeric protein signals, Current Opinion in Chemical Biology 2004, 8:610–616.
[21] Cook WJ, Jeffrey LC, Carson M, Chen Z, Pickart CM: Structure of a diubiquitin conjugate and a model for interaction with ubiquitin conjugating enzyme (E2). J Biol Chem 1992, 267:16467-16471.
[22] Sun L, Chen ZJ: The novel functions of ubiquitination in signaling. Curr Opin Cell Biol 2004, 16: 119-126.
[23] Hicke L, Dunn R: Regulation of membrane protein transport by ubiquitin and ubiquitin-binding proteins. Annu Rev Cell Dev Biol 2003, 19:141-172.
[24] Spence J, Gali RR, Dittmar G, Sherman F, Karin M, Finley D: Cell cycle-regulated modification of the ribosome by a variant multiubiquitin chain. Cell 2000, 102:67-76.
[25] M. E. Figuereido_Pereira, S. Yakushin and G. Cohen, Accumulation of ubiquitinated proteins in mouse neuronal cells induced by oxidative stress, Mol. Biol. Reports, 1997, 24, 35-38.
[26] M. Amici, K. Forti, C. Nobili, G. Lupidi, M. Angeletti, E. Fioretti, A.M. Eleuteri, Effect of neurotoxic metal ions on the proteolytic activities of the 20S proteasome from bovine brain, J Biol Inorg Chem (2002) 7: 750–756.
[27] I. Kim, C. H. Kim, J. H. Kim, J. Lee, J. J. Choi, Z. A. Chen, M. G. Lee, K. C. Chung, C. Y. Hsu, and Y. S. Ahn, Pyrrolidine dithiocarbamate and zinc inhibit proteasome-dependent proteolysis, Experimental Cell Research, 298, (2004) 229– 238.
[28] K. G. Daniel, P. Gupta, R. H. Harbach, W. C. Guida, Q. P. Dou, Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells, Biochemical Pharmacology 67 (2004) 1139–1151.
[29] K. G. Daniel, D. Chen, S. Orlu, Q. C. Cui, F. R. Miller and Q. P. Dou, Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells, Breast Cancer Research/R897.
[30] D. H. Hyun, D. A. Gray, B. Halliwell and P. Jenner, Interference with ubiquitination causes oxidative damage and increased protein nitration: implications for neurodegenerative diseases, Journal of Neurochemistry, 2004, 90, 422–430.
[31] Zecca L, Stroppolo A, Gatti A, Tampellini D, Toscani M, Gallorini M, Giaveri G, Arosio P, Santambrogio P, Fariello RG, Karatekin E, Kleinman MH, Turro N, Hornykiewicz O, Zucca FA, The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging, Proc Natl Acad Sci U S A, 2004, 101, 9843-9848. Epub 2004 Jun 21.
[32] Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR, Iron, brain ageing and neurodegenerative disorders, Nat Rev Neurosci, 2004, 5, 863-873.
[33] Paulus W, Jellinger K, The neuropathologic basis of different clinical subgroups of Parkinson's disease, J Neuropathol Exp Neurol, 1991, 50, 743-755.
[34] Dexter DT, Wells FR, Agid F, Agid Y, Lees AJ, Jenner P, Marsden CD, Increased nigral iron content in postmortem parkinsonian brain, Lancet, 1987, 2, 1219-1220.
[35] Zecca L, Fariello R, Riederer P, Sulzer D, Gatti A, Tampellini D, The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's disease, FEBS Lett, 2002, 510, 216-220.
[36] Shamoto-Nagai M, Maruyama W, Akao Y, Osawa T, Tribl F, Gerlach M, Zucca FA, Zecca L, Riederer P, Naoi M, Neuromelanin inhibits enzymatic activity of 26S proteasome in human dopaminergic SH-SY5Y cells, J Neural Transm, 2004, 111, 1253-1265.
[37] A. Favit, M. Grimaldi, and D. L, Alkon, Prevention of b-Amyloid Neurotoxicity by Blockade of the Ubiquitin–Proteasome proteolytic Pathway, J. Neurochem, 2000, 75, 1258–1263.

Parole Chiave

PEPTIDI, IONI METALLICI, STRESS OSSIDATIVO, SISTEMA UBIQUITINA-PROTEASOMA, COMPOSTI AD ATTIVITÀ CHELANTE ED ANTIOSSIDANTE, NEURODEGENERAZIONE, RELAZIONE STRUTTURA ATTIVITA'